Skip to main content

New story in Health from Time: Moderna’s COVID-19 Vaccine Shows Promise, Generating Positive Immune Responses in an Early Study



Earlier today, the biotech company Moderna reported positive results from a phase 1 study of its experimental COVID-19 vaccine, which was was among the first to begin testing in healthy human volunteers in mid-March.

The study, led by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, involves 45 healthy people who received one of three different doses of the vaccine. According to Moderna, there are encouraging early signs that the shot generates antibodies against the COVID-19 virus, SARS-CoV-2, in levels that were similar to or higher than those seen in the plasma of people who recovered from infections.

The phase 1 study is actually not designed to measure effectiveness of the vaccine—it is is focused primarily on safety. Nevertheless, the hints of efficacy emerging from the trial are encouraging. The level of antibodies seen in the participants show that the vaccine can attract and awaken the body’s immune response to mount a defense against SARS-CoV-2. The data also hinted that the higher doses prompted stronger immune responses.

In addition, the company reports that in a preliminary analysis, antibodies from eight of the participants (four given the low dose and four given the medium dose) appeared to neutralize the virus in the lab.

In the phase 1 study, the participants were all healthy volunteers aged 18 to 55 years. Those in the low- and medium-dose groups received two doses about a month apart, in order to properly prime the immune system for the most robust response. People in the highest dose group received only one inoculation. The results will likely be analyzed and reported in a scientific publication in coming weeks.

Based on these results, the phase 2 study, which the Food and Drug Administration (FDA) has cleared, will enroll around 600 healthy volunteers, will include just two doses—one that is slightly higher than the lowest dose, as well as the medium dose, since these appear to be sufficient to generate a relatively strong immune response. The company expects those trials to begin in June, and may include those at higher risk of exposure to SARS-CoV-2, such as health care workers. Those studies will determine which dose will be tested in the final, phase 3 studies that could begin as early as July. Based on the urgent need for a vaccine against COVID-19, on May 12 the FDA gave Moderna’s vaccine fast track status, which would expedite the regulatory agency’s review process.

These findings, though still early, are a validation of Moderna’s technology, which veers from the traditional vaccine design that generally depend on snippets of viral proteins or inactivated virus to activate the immune system. Moderna’s vaccine is made of mRNA from the virus, the genetic material that codes for proteins; after inoculation, it can prompt the body’s immune cells to recognize it as foreign and launch attacks against it. The company has been developing mRNA vaccines against a number of other disease, including respiratory syncytial virus, Zika and influenza.

Labels

Labels:

Popular posts from this blog

New story in Health from Time: Here’s How Quickly Coronavirus Is Spreading in Your State

The novel coronavirus pandemic is a global crisis, a national emergency and a local nightmare. But while a great deal of the focus in the U.S. has been on the federal government’s response, widely criticized as slow and halting , the picture on the ground remains very different in different parts of the country. A TIME analysis of the per capita spread of the epidemic in all 50 states and Washington, D.C. found considerable range in the rate of contagion, and, in some parts of the country, a significant disparity compared to the national figure. The U.S., unlike nations such as South Korea and now Italy , has yet to show signs of bringing the runaway spread of the virus under control. However, while no single state is yet showing strong signs of bending the curve , some are faring much worse than others. The following graphic plots the rise in the total confirmed cases of COVID-19 per 100,000 residents in each state, plotted by the day that each state reported its first case....
Read more

New video by gymvirtual on YouTube

Rutina para adelgazar | Ejercicios para perder peso en casa ♥ ♥ LÉEME / DESPLIÉGAME ♥ ♥ Hola a todos, hoy os traigo una rutina de cardio de 25 minutos para quemar grasa y adelgazar en casa. En la web https://ift.tt/39VJREp encontraréis los calendarios de entrenamiento tanto para principiantes como para avanzados. Si quieres conseguir tú transformación en solamente 12 semanas, entra ya en http://www.pgv12.com y elige el PLAN PGV12 que más se adapte a ti. Nuestro lema: YO PUEDO CON TODO Los hashtags: #GymVirtual #YPCT #YoPuedoConTodo #PGV12 ♡♡ ¡SUSCRÍBETE! ♡♡ http://www.youtube.com/user/gymvirtual ................................................................................................................................. ♡♡ PLAN DE ENTRENAMIENTO + NUTRICIÓN 12 SEMANAS♡♡ http://www.pgv12.com ................................................................................................................................. ♡♡¡ECHA UN VISTAZO A NUESTRA TIENDA ONLINE! ♡♡ https://ift.tt/2Un...
Read more

New story in Health from Time: After Cruise Ships and Nursing Homes, Will Universities Be the Next COVID-19 Tinderboxes?

The fall semester has yet to begin, but student athletes training for the season can already be found on college campuses across the U.S. And so can COVID-19. Since the start of July there have been at least two outbreaks among student athletes, coaches, and staff—with 37 infected at the University of North Carolina (UNC) Chapel Hill and 22 at Boise State . Clusters of infection have been traced to college town bars popular with students. A common misconception is that young people with COVID-19 don’t die and therefore college re-openings pose little risk. Sadly, this isn’t the case. COVID-19 deaths in the young are rare, but they happen. Universities across the U.S. are mourning the loss of students in the lead-up to the school year, including Joshua Bush , a 30-year old nursing student at the University of South Carolina, Trevor Syphus Lee , a 27-year old senior at Utah Valley University, and Juan Garcia , a 21-year old Penn State undergraduate. One might imagine th...
Read more